VANDA Pharmaceuticals - Investor Relations - IR Home

Investor Relations

Press Releases

Print Page Print Page
<< Back
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2015 Financial Results on February 10, 2016
Conference Call and Webcast to Follow

WASHINGTON, Jan. 22, 2016 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the fourth quarter of 2015 on Wednesday, February 10, 2016, after the market closes.

Vanda will host a conference call at 4:30 PM ET on Wednesday, February 10, 2016, during which management will discuss the fourth quarter and full year 2015 financial results and other corporate activities. To participate in the conference call, please dial 1-888-771-4371 (domestic) or 1-847-585-4405 (international) and use passcode 41672752.

The conference call will be broadcast simultaneously and archived on Vanda's website, www.vandapharma.com.  Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Wednesday, February 10, 2016, beginning at 7:00 PM ET and will be accessible until Wednesday, February 17, 2016, at 11:59 PM ET.  The replay call-in number is 1-888-843-7419 for domestic callers and 1-630-652-3042 for international callers.  The passcode number is 41672752.

ABOUT VANDA PHARMACEUTICALS INC.:
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapies addressing high unmet medical needs.  For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.

Investor Contact:
Jim Kelly
Senior Vice President & Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/vanda-pharmaceuticals-to-announce-fourth-quarter-and-full-year-2015-financial-results-on-february-10-2016-300208425.html

SOURCE Vanda Pharmaceuticals Inc.

Copyright © 2005-2024 Vanda Pharmaceuticals Inc. |